TCGA-A2-A3XS-01A-11R-A22U-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 34
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.310
- E2F_TARGETS+0.300
- PANCREAS_BETA_CELLS+0.190
- MYOGENESIS+0.180
- G2M_CHECKPOINT+0.110
- ALLOGRAFT_REJECTION+0.100
- APICAL_JUNCTION+0.100
- MYC_TARGETS_V2+0.100
- SPERMATOGENESIS+0.080
- WNT_BETA_CATENIN_SIGNALING+0.070
Top 10 suppressed
- PROTEIN_SECRETION-0.430
- ANDROGEN_RESPONSE-0.390
- UV_RESPONSE_DN-0.390
- TGF_BETA_SIGNALING-0.350
- ESTROGEN_RESPONSE_EARLY-0.330
- ADIPOGENESIS-0.300
- ANGIOGENESIS-0.280
- INTERFERON_ALPHA_RESPONSE-0.280
- INTERFERON_GAMMA_RESPONSE-0.260
- COMPLEMENT-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-60-2726-01A-01R-0851-07 | — | cohortSQ1 | 0.805 |
| 2 | AUR-AFR5-TTM1-A-1-1-R-A743-41 | — | E | 0.799 |
| 3 | AUR-AFEA-TTM1-A-1-1-R-A742-41 | — | E | 0.796 |
| 4 | TCGA-PL-A8LV-01A-21R-A41B-07 | — | E | 0.795 |
| 5 | TCGA-21-1082-01A-01R-0692-07 | — | cohortSQ1 | 0.787 |
| 6 | SRR1797257 | — | cohortSC | 0.786 |
| 7 | TCGA-37-A5EN-01A-21R-A26W-07 | — | cohortSQ2 | 0.771 |
| 8 | MDT-AP-1141 | Med | Medulloblastoma | 0.770 |
| 9 | SRR8943030 | — | — | 0.769 |
| 10 | MNG1078 | — | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |